Wall Street equity research analysts tracking AbbVie Inc. typically maintain a consensus rating leaning toward a moderate or strong buy, supported by strong performance in its diversified immunology and oncology portfolios. Analysts frequently highlight the smooth absorption of legacy patent expirations through newer growth drivers like Skyrizi and Rinvoq, robust cash flow generation, and a consistent history of dividend growth as key reasons for maintaining favorable investment recommendations.